Analysis of the Pachychoroid Phenotype in an Asian Population
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
The progression of uncomplicated pachychoroid phenotype to pachychoroid disease is not well established and the pathophysiology of these phenotypes remains unknown: specifically if the occurence of pachyvessels is the primary event, or develops secondary to the inner choroidal attenuation.
A longitudinal study of the pachychoroid phenotype will provide much needed information regarding the natural history of the pachychoroid phenotype. Secondly, a detailed chronicle of the choroidal alterations in the pachychoroid disease spectrum may yield insights into the pathogenesis, and facilitate the development of disease modulation strategies.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Gemmy Cheung, MBBS
- Phone Number: +65 83828173
- Email: gemmy.cheung.c.m@singhealth.com.sg
Study Contact Backup
- Name: Kelvin Teo, MBBS
- Phone Number: +65 98000002
- Email: kelvin.teo.y.c@singhealth.com.sg
Study Locations
-
-
-
Singapore, Singapore
- National University Hospital
-
Singapore, Singapore
- Singapore National Eye Centre
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Presence of uncomplicated and/or non-neovascular pachychoroid phenotype in at least one eye.
- Subfoveal choroidal thickness >300 microns on enhanced depth imaging optical coherence tomography for at least one eye
- Male or female patients above 45 years of age
- Willingness to undergo pupil dilation, and protocol- required procedures for both eyes
- Willing to provide written informed consent
Exclusion Criteria:
- Presence of disorders of the ocular media which interfere with visual acuity and other ocular assessments, including Spectral domain- optical coherence tomography during the study period
- Pregnant or nursing women
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of progression of pachychoroid phenotypes in 2 subtypes
Time Frame: 2 years observation
|
Two subtypes of pachychoroid phenotypes:
|
2 years observation
|
|
Risk factors for progression in 2 subtypes of pachychoroid phenotypes
Time Frame: 2 years
|
|
2 years
|
|
Assess the chronology of choroidal changes in patients
Time Frame: 2 years
|
Determine the occurence of pachyvessles is the primary event, or consequent to inner choroidal attenuation
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Xinyi Su, MBBS, National University Hospital, Singapore
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- R1661/58/2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pachychoroid Disease
-
NCT07260097RecruitingPachychoroid Disease
-
NCT07236671RecruitingPachychoroid Disease
-
NCT05662410CompletedPachychoroid Neovasculopathy
-
NCT06466018Recruiting
-
NCT05672979Not yet recruitingAge-Related Macular Degeneration | Pachychoroid Neovasculopathy
-
NCT07298174Not yet recruitingUveitis | Diabetic Retinopathy | Diabetic Macular Edema | Retinal Vein Occlusion | Geographic Atrophy | Myopia | Ocular Surface Disease | Stargardt Disease | Retinitis Pigmentosa (RP) | Vitreoretinal Disease
-
NCT04100889WithdrawnAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5
-
NCT04828837TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With Exacerbation
-
NCT05637801Active, not recruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia
-
NCT07217093Not yet recruitingInterstitial Lung Disease Due to Systemic Disease | Interstitial Lung Disease Due to Systemic Disease (Disorder) | Interstitial Lung Disease in Patients With Rheumatoid Arthritis